已收录 271055 条政策
 政策提纲
  • 暂无提纲
Alpha-Blockers for the Treatment of Prostatitis-Like Syndromes
[摘要] Prostatitis is a common medical diagnosis. The etiology of this symptomatic syndrome can be an acute or chronic bacterial infection, a noninfectious initiator (the most common cause), or iatrogenic heat or radiation; the syndrome may coexist with benign prostatic hyperplasia. Alpha-blockers have a role in the treatment of the prostatitis syndromes. In Category I, acute bacterial prostatitis, α-blockers have been shown to possibly ameliorate obstructive and irritative voiding symptoms. In Category II, chronic bacterial prostatitis, α-blockers seem to reduce the risk of clinical and bacteriological recurrence. In Category III, chronic pelvic pain syndrome, α-blockers improve symptoms and quality of life. Alpha-blockers also seem to ameliorate the symptoms and reduce the risk of acute urinary retention in patients who suffer from either heat- or radiation-induced prostatic inflammation. Alpha-blockers improve lower urinary tract symptoms, including pain, in patients who are diagnosed with both prostatitis and benign prostatic hyperplasia. Evidence has proven there is definitely a role for α-blockers in the management of the prostatitis syndromes.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 基础医学
[关键词] Alpha-blockers;Prostatitis syndromes;Lower urinary tract symptoms;Benign prostatic hyperplasia;CP/CPPS [时效性] 
   浏览次数:17      统一登录查看全文      激活码登录查看全文